202 related articles for article (PubMed ID: 27132755)
21. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis.
Lin L; Zhao YJ; Zhou HJ; Khoo AL; Teng M; Soh LB; Lim BP; Sim K
Int Clin Psychopharmacol; 2016 Mar; 31(2):84-92. PubMed ID: 26619182
[TBL] [Abstract][Full Text] [Related]
22. Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.
Barbosa WB; Costa JO; de Lemos LLP; Gomes RM; de Oliveira HN; Ruas CM; Acurcio FA; Barbui C; Bennie M; Godman B; Guerra AA
Appl Health Econ Health Policy; 2018 Oct; 16(5):697-709. PubMed ID: 30051254
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Allan E; Erdos J; Frisman LK; Xu W; Thomas J; Henderson W; Charney D
Arch Gen Psychiatry; 1999 Jun; 56(6):565-72. PubMed ID: 10359474
[TBL] [Abstract][Full Text] [Related]
24. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
[TBL] [Abstract][Full Text] [Related]
25. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].
Sacristán JA; Gómez JC; Salvador-Carulla L
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(4):225-34. PubMed ID: 9412161
[TBL] [Abstract][Full Text] [Related]
26. New vs. old antipsychotics: the Texas experience.
Reid WH
J Clin Psychiatry; 1999; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
Obradovic M; Mrhar A; Kos M
Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
30. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.
Ginsberg G; Shani S; Lev B
Pharmacoeconomics; 1998 Feb; 13(2):231-41. PubMed ID: 10178649
[TBL] [Abstract][Full Text] [Related]
31. Impact of newer antipsychotics on outcomes in schizophrenia.
Keks NA
Clin Ther; 1997; 19(1):148-58; discussion 126-7. PubMed ID: 9083717
[TBL] [Abstract][Full Text] [Related]
32. Atypical antipsychotics and formulary decisions.
Am J Manag Care; 1998 Jan; 4 Suppl():S8-12; discussion S12-4. PubMed ID: 10184948
[TBL] [Abstract][Full Text] [Related]
33. [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].
Dilla T; Prieto L; Ciudad A; Sacristán JA
Actas Esp Psiquiatr; 2004; 32(5):269-79. PubMed ID: 15529211
[TBL] [Abstract][Full Text] [Related]
34. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
[TBL] [Abstract][Full Text] [Related]
35. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine.
Davies LM; Barnes TR; Jones PB; Lewis S; Gaughran F; Hayhurst K; Markwick A; Lloyd H;
Value Health; 2008; 11(4):549-62. PubMed ID: 18179662
[TBL] [Abstract][Full Text] [Related]
38. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
Layton S; Barbeau M
Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
40. The cost-effectiveness of atypicals in the UK.
Heeg B; Buskens E; Botteman M; Caleo S; Ingham M; Damen J; de Charro F; van Hout B
Value Health; 2008 Dec; 11(7):1007-21. PubMed ID: 18489517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]